GLP1R and peripheral vascular disease: For example, Dotan et al. [22] suggested that among solid organ (kidney, liver, lung, heart) transplant recipients, GLP1-RA use may be linked to significantly lower risk of cardiovascular events, peripheral vascular disease, and mortality.